

Long-term Public Healthcare Burden Associated with Intimate Partner Violence among Canadian Women: A Cohort Study

Authors

Gabriel John Dusing¹, Beverley M. Essue², Patricia O'Campo^{1,3}, and Nicholas Metheny⁴

¹ MAP Center for Urban Health Solutions, Li Ka Shing Knowledge Institute, St Michael's Hospital, 30 Bond St, Toronto, ON M5B 1W8

² Institute for Health Policy, Management and Evaluation, University of Toronto, 155 College St, Toronto, ON M5T 3M7

³ Dalla Lana School of Public Health, University of Toronto, 155 College St, Toronto, ON M5T 3M7

⁴ Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, Atlanta, GA, USA 30322

Corresponding Author:

Gabriel John Dusing

MAP Center for Urban Health Solutions

Li Ka Shing Knowledge Institute, St Michael's Hospital

30 Bond St, Toronto, ON M5B 1W8

gabrieljdusing@gmail.com

Acknowledgements and Funding

Ethics approval was granted by the Research Ethics Board of [BLINDED FOR REVIEW] (REB# 20-120).

This work was supported by the Social Sciences and Humanities Research Council of Canada via an Insight grant to [BLINDED FOR REVIEW] (#435-2020-1410).

Statement on the use of artificial intelligence (AI): In the preparation of this manuscript, the AI tool ChatGPT, developed by OpenAI, was utilized for summarizing content, streamlining sentences, structuring sections, and answering specific queries related to the text. The use of ChatGPT facilitated the enhancement of the manuscript's clarity and logical coherence. However, the authors assume full responsibility for the final content and ethical compliance with publication standards. ChatGPT was not used for the collection and analysis of data or the production of images or graphical elements.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Intimate partner violence (IPV) is a major global health issue, yet few studies explore its long-term public healthcare burden in countries with universal healthcare systems. This study analyzes this burden among Canadian women using data from the Neighborhood Effects on Health and Wellbeing survey and Ontario Health Insurance Plan (OHIP) records from 2009-2020. We employed inverse probability weighting with regression adjustment to estimate differences in cumulative costs and OHIP billings between those reporting exposure to IPV during the survey and those who did not. Our sample included 1,094 women, with 38.12% reporting IPV exposure via the Hurt, Insult, Threaten, Scream scale. Findings show a significant public healthcare burden due to IPV: women reporting IPV in 2009 had an average of 17% higher healthcare costs and 41 additional OHIP billings (0.1732;95% CI: 0.0578-0.2886; 41.23;95% CI: 12.63-69.82). Policies prioritizing primary prevention and integration of trauma-informed care among healthcare providers are vital to alleviate the long-term burden on public health systems.

Keywords: intimate partner violence; cost of disease

Background

Upwards of 40% of cisgender, Canadian women have experienced some form of intimate partner violence (IPV) in their lifetime (1,2). Including aggressive, coercive, controlling, or abusive behaviors resulting in physical and non-physical harm (3), IPV occurs across social strata (4,5) and outside male-female relationships (6–8). However, the most widespread form of IPV is violence perpetrated against cisgender women by a cisgender male intimate partner (2,9).

IPV exposure is linked to health effects through causal pathways involving physical and psychological trauma, chronic stress, and control (Figure 1) (10). First, IPV may cause physical and psychological trauma, directly increasing the risk of physical disability (11) and poor mental health (9,12–17). Long-term, chronic stress may trigger endocrine and immune responses, leading to inflammation (18–20) and non-communicable diseases (6,11,21–24). Restrictions on autonomy are shown to lead to untreated sexually transmitted infections and gynecological issues (13,25,26) and delaying disclosure of health issues, impeding treatment of health conditions (27,28).

Empirical evidence supports the association between IPV exposure and long-term negative health effects. A 2021 study linking Manitoba court records with healthcare data showed that women exposed to IPV had a nearly sevenfold greater risk of physical injuries, with incidences of 55.8 per 1000 (exposed) versus 8.5 per 1000 (non-exposed) (29). A longitudinal Australian study showed that women exposed to IPV had consistently poorer general health over 16 years compared to non-exposed women (30). Long-term societal costs associated with spouse-perpetrated IPV were estimated to be CAD\$7.4 billion in 2009 (31), which is likely an underestimate given the underreporting of IPV (32–34), the limited scope of the study, and data constraints. Although some cost estimates of IPV exposure in countries with universal healthcare exist (35–37), extant literature centers the United States, limiting generalization to jurisdictions that have universal healthcare systems. Furthermore, much of the existing research in universal healthcare systems are cross-sectional (11,27,28,38), rely on a single item to identify IPV (28,35,36), use administrative records to capture the most severe forms of IPV (29,37,39), or is limited by small sample sizes (19,28).

This study aims to compare differences in cumulative cost and total number of billings by IPV exposure over ten years among a representative sample of women residing in Toronto, the most populous and diverse city in Canada (40). We hypothesize women who report IPV exposure will have greater public healthcare costs and more frequent billings over the subsequent ten years compared to women who did not report IPV in this context.

Methods

Study Cohort

The study sample was derived from the Neighbourhood Effects on Health and Well-being (NEHW), a cross-sectional study of 2,412 English-speaking residents (age 25-64) from 50 Toronto neighborhoods collected over 2009-2011 (41). NEHW had high response (>80%) and completion (>96%) rates, and utilized multistage random sampling to ensure the sample was representative of the socio-demographic and economic profile of Toronto. Participants from the NEHW study eligible for our analysis were (1) female; (2) completed the Hurt, Insult, Threaten, Scream (HITS) screener for IPV; and (3) provided a valid Ontario

Health Insurance Plan (OHIP) number at the time of survey completion. We then contracted ICES, the organization authorized by the Ontario government to house and link provincial health administrative data (42,43), to link these participants to their personal OHIP records from the time of survey completion (2009-2011) to the latest year available (2020). OHIP is Ontario's provincial healthcare plan, providing universal coverage for medical expenses, including all physician, emergency department, and hospital visits (44). All Canadian citizens, permanent residents, and non-citizens with employment authorization aged 25+ residing in Ontario are eligible for OHIP (45). The final study sample consisted of N=1,094 participants.

Exposure

NEHW queried participants about their experiences with IPV over the past decade using the HITS scale (46–48). HITS has high sensitivity (96%) and specificity (91%) (47) and evaluates IPV through four key behaviors: physical aggression, verbal insults/degradation, threatening harm, and yelling. Participants rate the occurrence of each behavior using a five-point Likert ranging from 1 - "never" to 5 - "frequently." The summed scores (range: 4-20) identify the presence and frequency of IPV, with a cutoff of 10 indicating a threshold of IPV exposure (47). Individuals meeting this cutoff formed the exposure group, while those who did not were designated as the comparison group.

Outcome

The main outcome of this study is the public healthcare burden assessed through the 1) cumulative costs; and 2) cumulative number of billings to OHIP. First, each survey participant's healthcare costs were measured through the natural log of each participant's cumulative OHIP expenditure (adjusted to 2019 values) from the time of survey completion to the end of the study period (March 31, 2020). The natural log of cumulative cost allows interpretation as a percentage change, facilitating comparability with other studies. Second, we summed the cumulative number of healthcare billings to OHIP over the study period for each participant.

Covariates

Statistical models used to adjust regression models (main analyses) and calculate propensity scores (supplementary analyses) included the following demographic and socio-economic characteristics known to be correlated with IPV exposure: year of birth (continuous); length of OHIP eligibility (continuous); has children (yes/no); and total household income in Canadian dollars (<\$15,000, \$15,000 - \$29,999, \$30,000-\$49,999, ≥ \$50,000, or not reported). Immigrant status (born in Canada or not) was included for being correlated with differences in health status (49,50) as was healthcare utilization (49,51,52). The Charlson Comorbidity Index (CCI) was included to capture the burden of chronic and comorbid conditions and was computed using OHIP records (53–55). The Ontario Marginalization Index (ON-Marg) of neighborhood-level material deprivation (continuous) (56), encapsulate difficulties in meeting essential needs and is calculated via metrics including income, housing quality, and educational attainment; such measures are linked to differential patterns of healthcare utilization (46,57) and IPV risk (58–60).

Analyses

Descriptive analyses assessed the association between sample characteristics and IPV exposure, using chi-square tests for categorical variables, t-tests for differences in means, and bivariate quantile regression for differences in medians (Table 1). We also included a table with the distribution of the top ten most common billing codes categorized by IPV exposure at survey completion (Table 2), highlighting where the health system's IPV costs are aggregated. Across all analyses, statistical significance was set at $\alpha=0.05$ and conducted using Stata 17 (61).

We used inverse probability weighting with regression adjustment (IPWRA) – a matching method – to assess the association between outcome and exposure. IPWRA has previously been used to evaluate the effect of financial programs in Mexico (62) and Bangladesh (63), and household access to clean water in India (64) on the risk of IPV among women in these countries. Matching with IPWRA has two stages. First, a model for the exposure status is fitted to obtain propensity scores representing the likelihood of treatment assignment, which are then used to weight each individual in the exposure group and their counterpart in the comparison (65). The second stage applies regression adjustment using these weights to estimate average treatment effects (ATE) and average treatment effects on the treated (ATET) to compute averages in the predicted outcomes (i.e., cumulative billings and log cumulative cost) by exposure status (IPV vs no IPV). The ATE measures the expected outcome differences between the exposure and comparison groups across the entire population, regardless of actual exposure status (66,67). The ATET measures expected outcome differences solely within the exposure group. The alignment of these estimates suggests that the findings may generalize beyond the study sample, within matched characteristics (68).

IPWRA is similar to other matching methods in that it balances the IPWRA-weighted distribution of observed covariates between exposure and control groups, approximating a randomized experiment using observational data. However, IPWRA is characterized as “doubly robust” for estimating treatment effects since it requires correct specification of only either the outcome or the propensity score model (69). For each model, covariate balance is assessed through a table of standardized differences and variance ratios for each covariate. Standardized differences between zero and 0.10 (70) and variance ratios close to one indicate negligible differences between exposure/comparison groups and attainment of covariate balance (67,70,71).

Sensitivity Analyses

To ensure the robustness of our results, conventional propensity score matching was conducted with the same outcomes and covariates as in our main analysis, consistent with methods from prior studies (62,64).

Results

Sample Characteristics

Table 1 presents key characteristics of the unmatched study sample by IPV exposure. Of the N=1,094 women in our study sample, 38.12% screened positive for IPV via

the HITS instrument within the decade before participating in NEHW. The median cumulative cost to OHIP over the study period for the exposure group was CAD\$37,839 (IQR: [21873,74140]), while the median cumulative cost of the comparison group was CAD\$34,997 (IQR: [19001,64320]). Likewise, the exposure group had more cumulative OHIP billings (median: 221; IQR: [140,353]) than the comparison group (median: 218; IQR: [127,346]). Although the exposure group appeared to have higher median cumulative OHIP costs and billings than the comparison, these unadjusted differences did not reach statistical significance.

Material deprivation, age, having children, immigrant status, and CCI were all found to be significantly associated with exposure status in univariate analyses, justifying their inclusion in the weighting stage of the IPWRA analysis. Exposed women appeared to live in significantly ($p=0.001$) more materially deprived neighborhoods indicated by a higher median material deprivation index (median:0.02; IQR: [-0.58,0.86]) than comparison group counterparts (median:-0.24; IQR: [-0.73,0.55]). The exposure group was younger with 30.69% of women under 40 years old, as opposed to only 18.75% in the comparison group ($p<0.001$). Additionally, 70.98% of the exposure group had children, contrasted with 63.52% of the comparison group ($p=0.025$). The exposure group (relative to the comparison group) had a higher proportion of those with a CCI of zero (27.82% vs 18.46%) ($p<0.0001$).

Further contextualizing healthcare billings by IPV exposure, Table 2 presents differences in the distribution of the top ten most common OHIP billings (72,73) by IPV status. Billing distribution appears to differ significantly by exposure ($p<0.0001$), most notably a higher frequency of billings for K197 "Individual out-patient psychotherapy - per unit." This code constituted 0.88% of billings in the comparison group and 2.05% of the exposure group.

Model Results

The IPWRA estimates for ATE and ATET are reported in Table 3. On average across the entire study population, assuming universal IPV exposure in a counterfactual scenario, the ATE was 0.1732 (95% CI: 0.0578-0.2886) for log cumulative cost and 41.23 (95%CI: 12.63-69.82) in cumulative billings, indicating a 17.32% elevation in healthcare costs and 41.23 additional billings over the ten-year study period. Meanwhile, the ATET, that is, the average effect among women in our study who screened positive for IPV using HITS, was 0.1731 (95% CI: 0.0595-0.2866) and 47.90 (95%CI: 18.54-77.27) for log cumulative cost and cumulative healthcare billings respectively. This indicates that women in our study sample who screened positive for IPV had healthcare costs that were approximately 17.31% higher than what they would have been had they not experienced IPV, and 47.90 additional billings. The similarity of the ATE and ATET results for both outcomes suggests that the treatment effect is likely generalizable to women in the wider population (68).

Supplementary Table 1 presents the standardized differences and variance ratios between covariates in the exposure and comparison groups, in both the matched and unmatched sample, for all four models: one estimating ATE and ATET for each outcome (cumulative OHIP billings and log cumulative OHIP cost). Covariate distribution was improved after application of IPWRA-derived weights, with most standardized differences falling below the pre-specified cutoff (0.10) (70) and variance ratios close to one.

The results derived from conventional propensity score matching are presented in Supplementary Table 2. The ATE and ATET for both cumulative OHIP billings and log

cumulative cost were consistent with our main analyses, albeit with reduced magnitude. Specifically, the ATE and ATET for log cumulative cost indicate 20.42% (95%CI: 7.37%-33.47%) and 19.20% (95%CI: 4.45%-33.95%) higher OHIP costs, respectively. Cumulative OHIP billings indicate an additional 34.87 billings (95%CI: 3.33-66.41) for ATE and 60.00 billings (95%CI: 26.54-93.45) for ATET.

Discussion

This study is among the first to assess the public healthcare burden associated with IPV-exposure using a representative sample directly linked to data from a universal healthcare provider. The exposure group, i.e., those who screened positive for IPV during the ten years before participating in NEHW, had 17% higher public healthcare costs and 43 additional healthcare billings over the subsequent 10-year period than the matched comparison group. The Canadian Institute for Health Information estimated that age- and sex-adjusted annual OHIP spending was \$5,248 per person (74). Based on our analysis, such IPV exposure incurs an additional \$892 per affected individual (17% of \$5,248). With Ontario's female population holding steady at around 7 million since 2011 (75), and assuming a conservative 13% have experienced IPV in the past year (76), the excess OHIP costs amount to approximately CAD\$811 million annually, or an additional CAD\$8.11 billion over the study period.

Comparison with Prior Literature

A prior American study found women experiencing lifetime IPV had 19% (95%CI: 13%-26%) higher healthcare costs than those who did not (77). Despite similar excess cost estimates, their cohort was derived from enrollees in a single health maintenance scheme, while ours is based on a representative sample linked to healthcare data from a universal provider. This distinction is crucial, where a publicly funded health system in Ontario, offering universal coverage, contrasts with a more selective single health maintenance organization in the US.

We found that the exposure group received outpatient mental healthcare at higher rates than the comparison group (2.05% vs. 0.88%); potentially explained by higher rates of poor mental health outcomes found in prior studies (12,78), for example, exposed women had 1.72 (95%CI: 1.28-2.31) higher odds of subsequent depressive symptoms, and 2.19 (95%CI: 1.39-3.45) higher odds of postpartum depression (14).

Strengths and Limitations

This study has several major strengths. The average follow-up time was 9.5 years. Follow-up was conducted using OHIP records, minimizing loss to follow-up except in cases of emigration from Ontario or death. Our study sample was drawn from Canada's largest and most diverse city using rigorous sampling methodologies (40,41). The use of quasi-experimental methods reduces confounding between IPV and long-term healthcare costs. These strengths and alignment of our findings with studies from other contexts and with our sensitivity analyses bolster the validity of our conclusions.

There are also several limitations. The HITS scale used to measure IPV, while having high sensitivity, specificity, and good concurrent validity with more comprehensive measures (47,79,80), lacks coverage of sexual violence, stalking, coercive control, and technology-facilitated violence. The extended HITS scale (79), which includes sexual IPV,

was unavailable during the NEHW study. IPV exposure was only recorded at baseline, despite attempts to track later exposures using ICD-10 codes (T74.0-T74.9, X85-Y09, Z63.0). We hypothesize these codes are underutilized as they are not billable under OHIP (81). Given its historical underreporting, individuals in the comparison group may have experienced but not disclosed IPV (82,83); this may be mitigated since HITS behavior-based and avoids labeling IPV as either violence or abuse, which likely depresses reporting of IPV (84,85). Finally, costs were confined to OHIP data, omitting out-of-pocket or privately insured expenses, which are non-trivial components of healthcare spending in Canada.

Conclusion

Policy Implications

Our findings identify IPV as a significant burden on Canada's healthcare system, emphasizing the need for policymakers to prioritize primary prevention as a cost-saving strategy. By addressing key social determinants (e.g., poverty, housing, gender inequality), governments with universal healthcare schemes can achieve long-term savings by reducing public healthcare costs for those at risk of IPV. This aligns with WHO and Canadian government recommendations for holistic, community-lead policies that prevent and mitigate IPV's effects through social norms and healthcare improvements, rather than punitive actions for perpetrators (86,87).

Primary prevention approaches must also be paired with improving screening of, and service availability for, survivors (88), so they can be connected to trauma- and violence-informed legal, mental health, employment, and housing services (89,90). Access to transitional and long-term housing, in particular, has been cited as vital for women seeking to leave a violent relationship (91). For example, new models of care currently being tested by members of this research team aim to mitigate long-term health effects and costs by allowing women and children to remain in the family home, providing wraparound support in a "Safe at Home" model (92). Furthermore, since women experiencing IPV interact with the healthcare system more frequently, all healthcare professionals with direct patient contact should be trained to recognize signs of IPV and provide prompt and appropriate referrals and support through screening at mental health, emergency, and other types of healthcare system interactions in which IPV survivors are overrepresented. This should be substantiated with institutional and system-level policy changes that encourage the use of IPV-related ICD codes and allow them to be billed as the health outcomes they are. Trauma-informed care and resource referral should be better integrated into healthcare systems, with policies at systems and institutional levels providing additional training and funding to wraparound services at discharge. Finally, additional IPV-related content in nursing, social work, and medical education enables professionals to improve patient-centered communication and care, potentially leading to earlier intervention in cases of violence (93).

Future Directions

Women experiencing IPV use outpatient mental health services at higher rates. Future studies could explore how IPV introduces delays and other barriers to mental healthcare. We also found evidence linking IPV with neighborhood-level material deprivation.

Future analyses could explore this relationship (using other neighborhood indicators) further, providing policymakers with evidence to develop effective community-based interventions that align and collaborate with healthcare systems.

Conclusions

The healthcare costs measured in these analyses, while significant, are but a reflection of the psychological distress, physical pain, and disruption that survivors of IPV experience. The findings in this study therefore serve as a call to action for policymakers, community leaders, and healthcare providers to increase investment in research, primary prevention, and policy solutions that aim to prevent and mitigate IPV.

Tables and Figures

Table 1: Sample characteristics at time of survey participation, unmatched (N=1,094)

	No IPV Reported within 10-years of Survey Participation		Screened Positive for IPV within 10-years of Survey Participation		Total	
	<i>N</i>	<i>Row %</i>	<i>N</i>	<i>Row %</i>	<i>N</i>	<i>Row %</i>
Totals	677	61.88	417	38.12	1,094	100
	<i>Median</i>	<i>Interquartile Range</i>	<i>Median</i>	<i>Interquartile Range</i>	<i>Median</i>	<i>Interquartile Range</i>
Cumulative Healthcare Cost (Standardized to 2019 Inflation)	34,997	[19001,64320]	37,839	[21873,74140]	35,745	[20072,67481]
Cumulative OHIP Billings	218	[127,346]	221	[140,353]	219	[133,351]
Neighborhood Material Deprivation Index	-0.24	[-0.73,0.55]	0.02	[-0.58,0.86]	-0.11	[-0.70,0.70]
	<i>Mean</i>	<i>Standard Deviation</i>	<i>Mean</i>	<i>Standard Deviation</i>	<i>Mean</i>	<i>Standard Deviation</i>
Log Total Years of OHIP Eligibility	12.41	1.37	12.44	1.30	12.42	1.35

	<i>N</i>	<i>Column %</i>	<i>N</i>	<i>Column %</i>	<i>N</i>	<i>Column %</i>
Age						
25-29	33	4.87	34	8.15	67	6.12
30-39	94	13.88	94	22.54	188	17.18
40-49	180	26.59	124	29.74	304	27.79
50-59	224	33.09	120	28.78	344	31.44
60+	146	21.57	45	10.79	191	17.46
Marital Status						
Unmarried	271	40.03	166	39.81	437	39.95
Married	406	59.97	251	60.19	657	60.05
Has Children						
No	247	36.48	121	29.02	368	33.64
Yes	430	63.52	296	70.98	726	66.36
Born in Canada?						
Yes	416	61.45	281	67.39	697	63.71
No	261	38.55	136	32.61	397	36.29
Employment Status						

Unemployed	202	29.84	120	28.78	322	29.43
Employed	475	70.16	297	71.22	772	70.57
Total Household Income (2009 CAD)						
<15,000	15	2.22	14	3.36	29	2.65
15,000 - 29,999	40	5.91	27	6.47	67	6.12
30,000-49,999	79	11.67	55	13.19	134	12.25
≥ 50,000	501	74.00	307	73.62	808	73.86
Not reported	42	6.20	14	3.36	56	5.12
Charlson Comorbidity Index						
0	125	18.46	116	27.82	241	22.03
1-2	333	49.19	208	49.88	541	49.45
3-4	132	19.50	54	12.95	186	17.00
5+	87	12.85	39	9.35	126	11.52

Table 2: Distribution of the top 10 most frequent OHIP billing codes by IPV status over the study period (2011-2020)

Billing Code	Description	No IPV Reported within 10-years of Survey Participation		Screened Positive for IPV within 10-years of Survey Participation		Row Totals	
		N	% of all billings	N	% of all billings	N	% of all billings
A007	Intermediate assessment or well baby care	17029	9.33%	12054	9.73%	29083	9.49%
X178	Mammogram - No Signs or Symptoms - Dedicated Equipment - bilateral	3823	2.09%	1928	1.56%	5751	1.88%
G313	Electrocardiogram - twelve lead - professional component - must include written interpretation	3359	1.84%	1918	1.55%	5277	1.72%
A001	Minor Assessment	2980	1.63%	1984	1.60%	4964	1.62%
Q012	After hours premium	2631	1.44%	2193	1.77%	4824	1.57%
K083	Specialist consultation or visit by telephone or video	2779	1.52%	1726	1.39%	4505	1.47%
G310	Electrocardiogram - twelve lead - technical component	2770	1.52%	1614	1.30%	4384	1.43%
K081	Intermediate assessment of a patient by telephone or video	2553	1.40%	1759	1.42%	4312	1.41%
K301	Telephone technology (audio only) used during the service	2505	1.37%	1729	1.40%	4234	1.38%
K197	Individual out-patient psychotherapy - per unit	1615	0.88%	2542	2.05%	4157	1.36%
All Billings		182532	100%	123926	100%	306458	100%


Pearson chi-square value = 964.97; p-value < 0.001

Table 3: Estimated Average Treatment Effects (ATE) and Average Treatment Effects on the Treated (ATET) for outcomes over the study period (2011-2020) estimated with Inverse Probability Weighting with Regression Adjustment. Exposure is IPV within 10-years of survey participation.

	Estimate	95% Confidence Interval	
	Log of Cumulative Healthcare Cost		
ATE	0.1732**	0.0578	0.2886
ATET	0.1731**	0.0595	0.2866
	Cumulative Number of OHIP Billings		
ATE	41.23**	12.63	69.82
ATET	47.90**	18.54	77.27

*p-value < 0.05, **p-value < 0.01, ***p-value < 0.001

Figure 1: Theoretical Mechanism Linking IPV Exposure to Negative Long-term Health Trajectories



References

1. Cotter A. Intimate partner violence in Canada, 2018: An overview. *Juristat Can Cent Justice Stat.* 2021 Apr 26;1,3-23.
2. Violence Against Women Prevalence Estimates [Internet]. [cited 2023 Sep 12]. Available from: <https://www.who.int/publications-detail-redirect/9789240022256>
3. Violence against women [Internet]. [cited 2023 Sep 12]. Available from: <https://www.who.int/news-room/fact-sheets/detail/violence-against-women>
4. Peitzmeier SM, Malik M, Kattari SK, Marrow E, Stephenson R, Agénor M, et al. Intimate Partner Violence in Transgender Populations: Systematic Review and Meta-analysis of Prevalence and Correlates. *Am J Public Health.* 2020 Sep;110(9):e1–14.
5. Kolbe V, Büttner A. Domestic Violence Against Men— Prevalence and Risk Factors. *Dtsch Arztebl Int* [Internet]. 2020 Aug 3 [cited 2023 Oct 23]; Available from: <https://www.aerzteblatt.de/10.3238/arztebl.2020.0534>
6. Liu M, Cai X, Hao G, Li W, Chen Q, Chen Y, et al. Prevalence of Intimate Partner Violence Among Men Who Have Sex With Men: An Updated Systematic Review and Meta-Analysis. *Sex Med.* 2021 Dec 1;9(6):100433.
7. Finneran C, Stephenson R. Intimate Partner Violence Among Men Who Have Sex With Men: A Systematic Review. *Trauma Violence Abuse.* 2013 Apr;14(2):168–85.
8. Badenes-Ribera L, Frias-Navarro D, Bonilla-Campos A, Pons-Salvador G, Monderde-i-Bort H. Intimate Partner Violence in Self-identified Lesbians: a Meta-analysis of its Prevalence. *Sex Res Soc Policy.* 2015 Mar;12(1):47–59.
9. Rivara F, Adhia A, Lyons V, Massey A, Mills B, Morgan E, et al. The Effects Of Violence On Health. *Health Aff (Millwood).* 2019 Oct;38(10):1622–9.
10. World Health Organization. Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence [Internet]. Geneva: World Health Organization; 2013 [cited 2023 Oct 2]. Available from: <https://iris.who.int/handle/10665/85239>
11. Coker AL, Smith PH, Fadden MK. Intimate Partner Violence and Disabilities among Women Attending Family Practice Clinics. *J Womens Health.* 2005 Nov;14(9):829–38.
12. O'Campo P, Kub J, Woods A, Garza M, Jones AS, Gielen AC, et al. Depression, PTSD, and Comorbidity Related to Intimate Partner Violence in Civilian and Military Women. *Brief Treat Crisis Interv.* 2006;6(2):99–110.
13. Barker LC, Stewart DE, Vigod SN. Intimate Partner Sexual Violence: An Often Overlooked Problem. *J Womens Health.* 2019 Mar;28(3):363–74.
14. Bacchus LJ, Ranganathan M, Watts C, Devries K. Recent intimate partner violence against women and health: a systematic review and meta-analysis of cohort studies. *BMJ Open.* 2018 Jul;8(7):e019995.
15. Pill N, Day A, Mildred H. Trauma responses to intimate partner violence: A review of current knowledge. *Aggress Violent Behav.* 2017;
16. Brown S, Seals J. Intimate partner problems and suicide: are we missing the violence? *J Inj Violence Res.* 2019 Jan;11(1):53–64.
17. Stewart DE, Vigod S, Riazantseva E. New Developments in Intimate Partner Violence and Management of Its Mental Health Sequelae. *Curr Psychiatry Rep.* 2015 Dec 28;18(1):4.
18. Yim IS, Kofman YB. The psychobiology of stress and intimate partner violence. *Psychoneuroendocrinology.* 2019 Jul 1;105:9–24.
19. Newton TL, Fernandez-Botran R, Miller JJ, Lorenz DJ, Burns VE, Fleming KN. Markers of Inflammation in Midlife Women with Intimate Partner Violence Histories. *J Womens Health.* 2011 Dec;20(12):1871–80.
20. Stubbs A, Szoek C. The Effect of Intimate Partner Violence on the Physical Health and Health-Related Behaviors of Women: A Systematic Review of the Literature. *Trauma Violence Abuse.* 2022 Oct;23(4):1157–72.

21. Stene LE, Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate Partner Violence and Cardiovascular Risk in Women: A Population-Based Cohort Study. *J Womens Health*. 2013 Mar;22(3):250–8.
22. Mason SM, Wright RJ, Hibert EN, Spiegelman D, Jun HJ, Hu FB, et al. Intimate Partner Violence and Incidence of Type 2 Diabetes in Women. *Diabetes Care*. 2013 Apr 13;36(5):1159–65.
23. Amodeo G, Trusso MA, Fagiolini A. Depression and Inflammation: Disentangling a Clear Yet Complex and Multifaceted Link. *Neuropsychiatry*. 2017;7(4):448–57.
24. Kim IB, Lee JH, Park SC. The Relationship between Stress, Inflammation, and Depression. *Biomedicines*. 2022 Aug;10(8):1929.
25. Paul P, Mondal D. Association Between Intimate Partner Violence and Contraceptive Use in India: Exploring the Moderating Role of Husband’s Controlling Behaviors. *J Interpers Violence*. 2022 Sep 1;37(17–18):NP15405–33.
26. Silverman JG, Raj A. Intimate Partner Violence and Reproductive Coercion: Global Barriers to Women’s Reproductive Control. *PLOS Med*. 2014 Sep 16;11(9):e1001723.
27. Massetti GM, Townsend JS, Thomas CC, Basile KC, Richardson LC. Healthcare Access and Cancer Screening Among Victims of Intimate Partner Violence. *J Womens Health*. 2018 May;27(5):607–14.
28. Joshi M, Thomas KA, Sorenson SB. “I Didn’t Know I Could Turn Colors”: Health Problems and Health Care Experiences of Women Strangled by an Intimate Partner. *Soc Work Health Care*. 2012 Oct 1;51(9):798–814.
29. Nesca M, Au W, Turnbull L, Brownell M, Brownridge DA, Urquia ML. Intentional injury and violent death after intimate partner violence. A retrospective matched-cohort study. *Prev Med*. 2021 Aug 1;149:106616.
30. Loxton D, Dolja-Gore X, Anderson AE, Townsend N. Intimate partner violence adversely impacts health over 16 years and across generations: A longitudinal cohort study. Dalby AR, editor. *PLOS ONE*. 2017 Jun 5;12(6):e0178138.
31. Government of Canada D of J. Highlights - An Estimation of the Economic Impact of Spousal Violence in Canada, 2009 [Internet]. 2011 [cited 2023 Oct 23]. Available from: https://www.justice.gc.ca/eng/rp-pr/cj-jp/fv-vf/rr12_7/p0.html
32. Smith MD. Enhancing the Quality of Survey Data on Violence against Women: A Feminist Approach. *Gend Soc*. 1994;8(1):109–27.
33. Palermo T, Bleck J, Peterman A. Tip of the Iceberg: Reporting and Gender-Based Violence in Developing Countries. *Am J Epidemiol*. 2014 Mar 1;179(5):602–12.
34. Abramsky T, Harvey S, Moshia N, Mtolela G, Gibbs A, Mshana G, et al. Longitudinal inconsistencies in women’s self-reports of lifetime experience of physical and sexual IPV: evidence from the MAISHA trial and follow-on study in North-western Tanzania. *BMC Womens Health*. 2022 Apr 15;22(1):120.
35. William J, Loong B, Hanna D, Parkinson B, Loxton D. Lifetime health costs of intimate partner violence: A prospective longitudinal cohort study with linked data for out-of-hospital and pharmaceutical costs. *Econ Model*. 2022 Nov 1;116:106013.
36. Jónasdóttir D, Thorsteinsdóttir T, Ásgeirsdóttir TL, Lund SH, Arnarsson EÖ, Ashikali E, et al. Women and intimate partner violence: Prevalence of hospital visits and nature of injuries in the Icelandic population. *Scand J Public Health*. 2021 May 1;49(3):260–7.
37. Kruse M, Sørensen J, Brønnum-Hansen H, Helweg-Larsen K. The Health Care Costs of Violence Against Women. *J Interpers Violence*. 2011 Nov 1;26(17):3494–508.
38. Bosch J, Weaver TL, Arnold LD, Clark EM. The Impact of Intimate Partner Violence on Women’s Physical Health: Findings From the Missouri Behavioral Risk Factor Surveillance System. *J Interpers Violence*. 2017 Nov;32(22):3402–19.
39. Chandan JS, Thomas T, Raza K, Bradbury-Jones C, Taylor J, Bandyopadhyay S, et al. Intimate Partner Violence and the Risk of Developing Fibromyalgia and Chronic Fatigue Syndrome. *J Interpers Violence*. 2021 Nov 1;36(21–22):NP12279–98.
40. Government of Canada SC. Population estimates, July 1, by census metropolitan area and census agglomeration, 2016 boundaries [Internet]. 2019 [cited 2024 Apr 24]. Available from: <https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710013501>

41. O'Campo P, Wheaton B, Nisenbaum R, Glazier RH, Dunn JR, Chambers C. The Neighbourhood Effects on Health and Well-being (NEHW) study. *Health Place*. 2015 Jan 1;31:65–74.
42. ICES [Internet]. [cited 2023 Jul 31]. ICES | About Us | Community of Research, Data & Clinical Experts. Available from: <https://www.ices.on.ca/our-organization/>
43. Schull M, Azimae M, Marra M, Cartagena R, Vermeulen M, Ho M, et al. ICES: Data, Discovery, Better Health. *Int J Popul Data Sci*. 4(2):1135.
44. What OHIP covers | ontario.ca [Internet]. [cited 2024 Mar 27]. Available from: <http://www.ontario.ca/page/what-ohip-covers>
45. Apply for OHIP and get a health card | ontario.ca [Internet]. [cited 2023 Jul 31]. Available from: <http://www.ontario.ca/page/apply-ohip-and-get-health-card>
46. Kirst M, Lazgare LP, Zhang YJ, O'Campo P. The Effects of Social Capital and Neighborhood Characteristics on Intimate Partner Violence: A Consideration of Social Resources and Risks. *Am J Community Psychol*. 2015 Jun 1;55(3):314–25.
47. Sherin KM, Sinacore JM, Li XQ, Zitter RE, Shakil A. HITS: a short domestic violence screening tool for use in a family practice setting. *Fam Med*. 1998;30(7):508–12.
48. Attala JM, Hudson WW, McSweeney M, Features Submission HC. A Partial Validation of Two Short-Form Partner Abuse Scales. *Women Health*. 1994 May 23;21(2–3):125–39.
49. McDonald JT, Kennedy S. Insights into the 'healthy immigrant effect': health status and health service use of immigrants to Canada. *Soc Sci Med*. 2004 Oct 1;59(8):1613–27.
50. Siddiqi A, Ornelas IJ, Quinn K, Zuberi D, Nguyen QC. Societal context and the production of immigrant status-based health inequalities: A comparative study of the United States and Canada. *J Public Health Policy*. 2013 May 1;34(2):330–44.
51. Ravichandiran N, Mathews M, Ryan BL. Utilization of healthcare by immigrants in Canada: a cross-sectional analysis of the Canadian Community Health Survey. *BMC Prim Care*. 2022 Apr 6;23(1):69.
52. Lebrun LA. Effects of length of stay and language proficiency on health care experiences among Immigrants in Canada and the United States. *Soc Sci Med*. 2012 Apr 1;74(7):1062–72.
53. Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. *Psychother Psychosom*. 2022 Jan 6;91(1):8–35.
54. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. *J Clin Epidemiol*. 2004 Dec 1;57(12):1288–94.
55. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol*. 1992;45(6):613–9.
56. Matheson FI. 2011 Ontario Marginalization Index: User guide [Internet]. Ontario Agency for Health Protection and Promotion (Public Health Ontario); 2017. Available from: <https://www.publichealthontario.ca/-/media/documents/O/2017/on-marg-user-2011.pdf>
57. Hafez E, Kitchen C, Pandya C, Kharrazi H. Assessing Patient and Community-Level Social Factors; The Synergistic Effect of Social Needs and Social Determinants of Health on Healthcare Utilization at a Multilevel Academic Healthcare System. *J Med Syst*. 2023 Sep 1;47(1):95.
58. Bonomi AE, Trabert B, Anderson ML, Kernic MA, Holt VL. Intimate Partner Violence and Neighborhood Income: A Longitudinal Analysis. *Violence Women*. 2014 Jan;20(1):42–58.
59. Yakubovich AR, Heron J, Feder G, Fraser A, Humphreys DK. Long-term Exposure to Neighborhood Deprivation and Intimate Partner Violence Among Women: A UK Birth Cohort Study. *Epidemiology*. 2020 Mar;31(2):272–81.
60. Cunradi CB, Caetano R, Clark C, Schafer J. Neighborhood Poverty as a Predictor of Intimate Partner Violence Among White, Black, and Hispanic Couples in the United States: A Multilevel Analysis. *Ann Epidemiol*. 2000;10(5):297–308.
61. StataCorp. Stata Statistical Software: Release 17 [Internet]. College Station, TX: StataCorp LLC; 2021. Available from: <https://www.stata.com/stata17/>
62. Canedo AP, Morse SM. An Estimation of the Effect of Women's Employment on the

- Prevalence of Intimate Partner Violence in Mexico. *J Interpers Violence*. 2021 Oct 1;36(19–20):NP10594–618.
63. Yount KM, Cheong YF, Khan Z, Miedema SS, Naved RT. Women's participation in microfinance: Effects on Women's agency, exposure to partner violence, and mental health. *Soc Sci Med*. 2021 Feb 1;270:113686.
 64. Bandyopadhyay S, Sarkar S, Sensarma R. The association between access to key household resources and violence against women. *Sci Rep*. 2023 Jul 28;13(1):12278.
 65. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med*. 2015;34(28):3661–79.
 66. Basu A, Unuigbo A, Masseria C. Understanding differences between what alternate propensity score methods estimate. *J Manag Care Spec Pharm*. 2023 Apr;29(4):10.18553/jmcp.2023.29.4.391.
 67. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivar Behav Res*. 2011 May 31;46(3):399–424.
 68. Garrido MM, Dowd B, Hebert PL, Maciejewski ML. Understanding Treatment Effect Terminology in Pain and Symptom Management Research. *J Pain Symptom Manage*. 2016 Sep;52(3):446–52.
 69. Wooldridge JM. Inverse probability weighted estimation for general missing data problems. *J Econom*. 2007 Dec;141(2):1281–301.
 70. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med*. 2009;28(25):3083–107.
 71. Zhang Z, Kim HJ, Lonjon G, Zhu Y. Balance diagnostics after propensity score matching. *Ann Transl Med*. 2019 Jan;7(1):16.
 72. Government of Ontario M of H and LTC. OHIP - Bulletins - Health Care Professionals - MOHLTC [Internet]. Government of Ontario, Ministry of Health and Long-Term Care; [cited 2023 Sep 12]. Available from: <https://health.gov.on.ca/en/pro/programs/ohip/sob/>
 73. OHIP Billing Codes [Internet]. Dr.Bill. [cited 2023 Sep 12]. Available from: https://www.dr-bill.ca/ohip_billing_codes
 74. Age-Adjusted Public Spending per Person · CIHI [Internet]. [cited 2024 Mar 28]. Available from: <https://yourhealthsystem.cihi.ca/hsp/inbrief?lang=en#!/indicators/014/age-adjusted-public-spending-per-person;/mapC1;mapLevel2;/>
 75. Statistics Canada. Population estimates on July 1, by age and gender [Internet]. [object Object]; 2017 [cited 2024 Mar 28]. Available from: <https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501>
 76. Sardinha L, Maheu-Giroux M, Stöckl H, Meyer SR, García-Moreno C. Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018. *The Lancet*. 2022 Feb;399(10327):803–13.
 77. Rivara FP, Anderson ML, Fishman P, Bonomi AE, Reid RJ, Carrell D, et al. Healthcare Utilization and Costs for Women with a History of Intimate Partner Violence. *Am J Prev Med*. 2007 Feb 1;32(2):89–96.
 78. Devries KM, Mak JY, Bacchus LJ, Child JC, Falder G, Petzold M, et al. Intimate Partner Violence and Incident Depressive Symptoms and Suicide Attempts: A Systematic Review of Longitudinal Studies. *PLOS Med*. 2013 May 7;10(5):e1001439.
 79. Chan C, Chan Y, Au A, Cheung G. Reliability and Validity of the “Extended - Hurt, Insult, Threaten, Scream” (E-Hits) Screening Tool in Detecting Intimate Partner Violence in Hospital Emergency Departments in Hong Kong. *Hong Kong J Emerg Med*. 2010;17(2):109–17.
 80. Shakil A, Donald S, Sinacore JM, Krepcho M. Validation of the HITS domestic violence screening tool with males. *Fam Med*. 2005 Mar;37(3):193–8.
 81. Olive P. Intimate partner violence and clinical coding: issues with the use of the International Classification of Disease (ICD-10) in England. *J Health Serv Res Policy*.

- 2018 Oct 1;23(4):212–21.
82. Agüero J, Frisancho V. Misreporting in Sensitive Health Behaviors and Its Impact on Treatment Effects: An Application to Intimate Partner Violence.
 83. Chan KL. Gender differences in self-reports of intimate partner violence: A review. *Aggress Violent Behav.* 2011 Mar 1;16(2):167–75.
 84. Hamby SL, Gray-Little B. Labeling Partner Violence: When Do Victims Differentiate Among Acts? *Violence Vict.* 2000 Jan 1;15(2):173–86.
 85. Percy A, Mayhew P. Estimating Sexual Victimization in a National Crime Survey: A New Approach. *Stud Crime Crime Prev.* 1997;6 (2):125–50.
 86. Courage to Act [Internet]. 2021 [cited 2023 Oct 3]. 12 Policy Recommendations from Consultations to Inform Canada’s National Action Plan To End GBV. Available from: <https://www.couragetoact.ca/blog/nap-policy-recommendations>
 87. Responding to intimate partner violence and sexual violence against women – Summary [Internet]. [cited 2023 Oct 3]. Available from: <https://www.who.int/publications-detail-redirect/WHO-RHR-13.10>
 88. MacMillan HL, Wathen CN, Jamieson E, Boyle MH, Shannon HS, Ford-Gilboe M, et al. Screening for Intimate Partner Violence in Health Care Settings: A Randomized Trial. *JAMA.* 2009 Aug 5;302(5):493–501.
 89. Wathen CN, Mantler T. Trauma- and Violence-Informed Care: Orienting Intimate Partner Violence Interventions to Equity. *Curr Epidemiol Rep.* 2022 Dec 1;9(4):233–44.
 90. Lee E, Kourgiantakis T, Lyons O, Prescott-Cornejo A. A trauma-informed approach in Canadian mental health policies: A systematic mapping review. *Health Policy.* 2021 Jul;125(7):899–914.
 91. Iyengar R, Sabik L. The Dangerous Shortage Of Domestic Violence Services: An analysis suggests that more than one in ten victims in a twenty-four-hour period asked for—but didn’t get—help. *Health Aff (Millwood).* 2009 Jan;28(Supplement 1):w1052–65.
 92. Solutions Network: Safe at Home [Internet]. MAP Centre for Urban Health Solutions. [cited 2024 Apr 25]. Available from: <https://maphealth.ca/safe-at-home/>
 93. Rittenberg E. To Treat My Patient, I Had To Understand Her Trauma: A physician writes about caring for a patient struggling with past trauma and about the broader policy and clinical landscape of trauma-informed health care. *Health Aff (Millwood).* 2020 Jan 1;39(1):161–4.